Translational eradication approaches

Area of Science:

• Virology
• Immunology
• Molecular Biology

Background:

• HIV-1 cure remains elusive despite significant advances in antiretroviral therapy.
• Persistent HIV-1 reservoirs evade immune surveillance and antiretroviral drugs, leading to viral rebound upon treatment interruption.
• Life-long antiretroviral therapy is not a sustainable solution for all patients.

Purpose of the Study:

• To review recent developments in understanding HIV-1 persistence.
• To explore novel therapeutic strategies targeting HIV-1 reservoirs.
• To propose a combined approach for HIV-1 eradication.

Main Methods:

• Review of in vitro studies on novel drug candidates like IL-7, prostratin, and HDAC inhibitors.
• Evaluation of emerging technologies such as immunotoxins, RNA silencing, and gene therapy.
• Analysis of clinical trial data for new HIV-1 persistence-targeting agents.

Main Results:

• Non-specific immune stimulation (e.g., IL-2) has shown limited success in reservoir reduction.
• Novel agents including IL-7, prostratin, and HDAC inhibitors demonstrate significant in vitro potential.
• Early clinical data with HDAC inhibitors offer renewed optimism for targeting HIV-1 reservoirs.
• Advancements in immunotoxins, RNA silencing, and gene therapy provide new avenues for HIV-1 control.

Conclusions:

• A multi-pronged, stepwise therapeutic strategy is necessary to effectively target and eliminate HIV-1 reservoirs.
• Further proof-of-concept trials are required to validate the efficacy of combined approaches.
• Overcoming HIV-1 persistence is critical for achieving a functional cure.